RxDoctor Payments Data

Dipal Shah, DO

Internal Medicine · Arlington Heights, ILNPI 1235386160

Payments from drug & device makers

$1,114in general payments, 2019–2025

Across 12 payments — averaging $92.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$600
  • Dexcom, Inc.$157
  • Genentech USA, Inc.$142
  • Lilly USA, LLC$103
  • Novo Nordisk$65
  • Stryker$48

What the payments were for

  • Food & beverage$45040%
  • Education$66460%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott3$600
Dexcom, Inc.4$157
Genentech USA, Inc.1$142
Lilly USA, LLC1$103
Novo Nordisk2$65
Stryker1$48

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,114 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$142,708
Medicare patients
522
Services billed
2,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide401$684,685
JardianceEmpagliflozin155$213,632
RybelsusSemaglutide68$135,692
TrulicityDulaglutide70$121,771
MounjaroTirzepatide61$96,211
Tresiba Flextouch U-200Insulin Degludec53$95,748
Tresiba Flextouch U-100Insulin Degludec109$86,154
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/737$53,284
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog62$52,703
Fiasp FlextouchInsulin Aspart (Niacinamide)39$48,898
Humulin R U-500 KwikpenInsulin Regular, Human18$39,934
Novolog FlexpenInsulin Aspart89$39,367
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog66$37,339
Humalog Kwikpen U-100Insulin Lispro89$29,475
Lantus SolostarInsulin Glargine,hum.Rec.Anlog154$24,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$65$834,301505 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$103$228,067165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →